{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:53:33Z","timestamp":1780635213876,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2019-089"],"award-info":[{"award-number":["2019-089"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00428-025-04345-6","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T03:45:29Z","timestamp":1765165529000},"page":"511-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Orthogonal validation of anaplastic lymphoma kinase (ALK) immunohistochemistry with molecular analysis for ALK gene rearrangement is required to finetune staining protocols with the D5F3 clone and can impact external quality assessment"],"prefix":"10.1007","volume":"488","author":[{"given":"Ibrahim","family":"Kassem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Van Essche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7947-4561","authenticated-orcid":false,"given":"Delphine","family":"Hoton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-5304","authenticated-orcid":false,"given":"Dominique","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Camby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-France","family":"Dekairelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-0204","authenticated-orcid":false,"given":"Yves","family":"Guiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-3355","authenticated-orcid":false,"given":"Louis","family":"Libbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-928X","authenticated-orcid":false,"given":"Mieke R.","family":"Van Bockstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"4345_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41586-021-04140-8","volume":"600","author":"AV Reshetnyak","year":"2021","unstructured":"Reshetnyak AV, Rossi P, Myasnikov AG et al (2021) Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature 600:153\u2013157","journal-title":"Nature"},{"key":"4345_CR2","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood.V89.4.1394","volume":"89","author":"K Pulford","year":"1997","unstructured":"Pulford K, Lamant L, Morris SW et al (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394\u20131404","journal-title":"Blood"},{"key":"4345_CR3","unstructured":"Kristoffersen HL, Emanuelsen L, Nielsen S (2025) Assessment run 73 2025 lung anaplastic lymphoma kinase (ALK (lung)). In: https:\/\/www.nordiqc.org\/downloads\/assessments\/201_14.pdf"},{"key":"4345_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/PAI.0000000000000444","volume":"25","author":"EE Torlakovic","year":"2016","unstructured":"Torlakovic EE, Cheung CC, Corrado D\u2019arrigo Y et al (2016) Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine-Part 2: immunohistochemistry test performance characteristics. Appl Immunohistochem Mol Morphol 25:79\u201385","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4345_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/ejh.12360","volume":"93","author":"TA Eyre","year":"2014","unstructured":"Eyre TA, Khan D, Hall GW, Collins GP (2014) Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eur J Haematol 93:455\u2013468","journal-title":"Eur J Haematol"},{"key":"4345_CR6","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1097\/00000478-200111000-00003","volume":"25","author":"JR Cook","year":"2001","unstructured":"Cook JR, Dehner LP, Collins MH et al (2001) Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 25:1364\u20131371","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"4345_CR7","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.humpath.2009.01.012","volume":"40","author":"JM Boland","year":"2009","unstructured":"Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MRE, Wang X, Peterson LM, Halling KC, Oliveira AM, Aubry MC, Yi ES (2009) Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 40(8):1152\u20131158. https:\/\/doi.org\/10.1016\/j.humpath.2009.01.012","journal-title":"Hum Pathol"},{"key":"4345_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/PAS.0000000000000801","volume":"41","author":"JD Haimes","year":"2017","unstructured":"Haimes JD, Stewart CJR, Kudlow BA et al (2017) Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1. Am J Surg Pathol 41:773\u2013780","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"4345_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PGP.0000000000000858","volume":"42","author":"CJ Bowman","year":"2023","unstructured":"Bowman CJ, Medeiros F, Fadare O, Sangoi AR, Horvai AE, Devine WP, McCluggage WG, Rabban JT (2023) ALK immunoexpression is specific for inflammatory myofibroblastic tumor among vulvovaginal mesenchymal neoplasms. Int J Gynecol Pathol 42(1):1\u201310. https:\/\/doi.org\/10.1097\/PGP.0000000000000858","journal-title":"Int J Gynecol Pathol"},{"key":"4345_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566","journal-title":"Nature"},{"issue":"1","key":"4345_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","volume":"3","author":"K Inamura","year":"2008","unstructured":"Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Lim Choi Y, Niki T, Mano H, Ishikawa Y (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3(1):13\u201317. https:\/\/doi.org\/10.1097\/JTO.0b013e31815e8b60","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4345_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00449-x","volume":"7","author":"A Shreenivas","year":"2023","unstructured":"Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R (2023) ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol 7(1):101. https:\/\/doi.org\/10.1038\/s41698-023-00449-x","journal-title":"NPJ Precis Oncol"},{"key":"4345_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/ajcp\/aqac043","volume":"158","author":"D Martin","year":"2022","unstructured":"Martin D, Smith SC, Chesney A et al (2022) Too sensitive or just right? A comparison of two alK antibodies (D5F3 and alK1) for assessment of anaplastic large cell lymphoma. Am J Clin Pathol 158:283\u2013290","journal-title":"Am J Clin Pathol"},{"key":"4345_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.humpath.2018.02.021","volume":"80","author":"M Fujimoto","year":"2018","unstructured":"Fujimoto M, Togashi Y, Matsuzaki I, Baba S, Takeuchi K, Inaba Y, Jinnin M, Murata S-I (2018) A case report of atypical Spitz tumor harboring a novel MLPH-ALK gene fusion with discordant ALK immunohistochemistry results. Hum Pathol 80:99\u2013103. https:\/\/doi.org\/10.1016\/j.humpath.2018.02.021","journal-title":"Hum Pathol"},{"issue":"3","key":"4345_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00428-016-1969-y","volume":"469","author":"D Taheri","year":"2016","unstructured":"Taheri D, Zahavi DJ, Del Carmen Rodriguez M, Meliti A, Rezaee N, Yonescu R, Ricardo BFP, Dolatkhah S, Ning Yi, Bishop JA, Netto GJ, Sharma R (2016) For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. Virchows Arch 469(3):345\u2013350. https:\/\/doi.org\/10.1007\/s00428-016-1969-y","journal-title":"Virchows Arch"},{"key":"4345_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-023-03605-7","volume":"483","author":"KJ Fritchie","year":"2023","unstructured":"Fritchie KJ, Dermawan JK, Astbury C et al (2023) Novel NONO::TFE3 fusion and ALK co-expression identified in a subset of cutaneous microcystic\/reticular schwannoma. Virchows Arch 483:237\u2013243","journal-title":"Virchows Arch"},{"key":"4345_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/gcc.23038","volume":"61","author":"N Georgantzoglou","year":"2022","unstructured":"Georgantzoglou N, Green D, Winnick KN et al (2022) Molecular investigation of ALK-rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion-independent transcription activation. Genes Chromosomes Cancer 61:471\u2013480","journal-title":"Genes Chromosomes Cancer"},{"key":"4345_CR18","first-page":"147","volume":"11","author":"H Uruga","year":"2018","unstructured":"Uruga H, Mino-Kenudson M (2018) ALK (D5F3) CDx: an immunohistochemistry assay to identify alk-positive NSCLC patients. Pharmacogenomics Pers Med 11:147\u2013155","journal-title":"Pharmacogenomics Pers Med"},{"key":"4345_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PAI.0000000000000470","volume":"25","author":"EE Torlakovic","year":"2017","unstructured":"Torlakovic EE, Cheung CC, Corrado D\u2019arrigo Y et al (2017) Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine. Part 3: technical validation of immunohistochemistry (IHC) assays in clinical IHC laboratories. Appl Immunohistochem Mol Morphol 25:151\u2013159","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4345_CR20","unstructured":"Nordic Immunohistochemical Quality Control (2022) Recommended protocol for ALK (lung), obtained in run 65, 11 March 2022. In: https:\/\/www.nordiqc.org\/protocol_view.php?id=44219 (assessed on 11 July 2025)"},{"key":"4345_CR21","unstructured":"ComPerMed (2024) Lung cancer workflow 2 for non-squamous cell carcinoma. In: https:\/\/www.compermed.be\/en\/workflows\/lung"},{"key":"4345_CR22","volume":"1","author":"SHI Ou","year":"2020","unstructured":"Ou SHI, Zhu VW, Nagasaka M (2020) Catalog of 5\u2019 fusion partners in ALK-positive NSCLC circa 2020. JTO Clin Res Rep 1:100015","journal-title":"JTO Clin Res Rep"},{"key":"4345_CR23","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/1759-7714.15445","volume":"15","author":"YE Sung","year":"2024","unstructured":"Sung YE, Kim M (2024) Revisiting ALK (D5F3) immunohistochemistry: insights into focal staining and neuroendocrine differentiation. Thorac Cancer 15:2175\u20132184","journal-title":"Thorac Cancer"},{"issue":"8","key":"4345_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.5858\/arpa.2023-0229-OA","volume":"148","author":"A Nambirajan","year":"2024","unstructured":"Nambirajan A, Sood R, Khatoon W, Malik PS, Mohan A, Jain D (2024) Concordance of immunohistochemistry and fluorescence in situ hybridization in the detection of anaplastic lymphoma kinase (ALK) and Ros proto-oncogene 1 (ROS1) gene rearrangements in non-small cell lung carcinoma a 4.5-year experience highlighting challenges and pitfalls. Arch Pathol Lab Med 148(8):928\u2013937. https:\/\/doi.org\/10.5858\/arpa.2023-0229-OA","journal-title":"Arch Pathol Lab Med"},{"key":"4345_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.lungcan.2016.11.001","volume":"103","author":"I Demidova","year":"2017","unstructured":"Demidova I, Grinevich V, Avdalian A, Imyanitov E, Gikalo M, Savelov N, Novikova I, Samuilenkova O, Tiurin V, Ulianova E, Tsimafeyeu I, Tjulandin S (2017) Detection of ALK rearrangements in 4002 Russian patients: the utility of different diagnostic approaches. Lung Cancer 103:17\u201323. https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.001","journal-title":"Lung Cancer"},{"issue":"6","key":"4345_CR26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.5858\/arpa.2012-0762-OA","volume":"138","author":"I Demidova","year":"2014","unstructured":"Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, Stroiakovaski D, Popov M, Laktionov K, Gutorov S, Smolin A, Olshanskaya Y, Obukhova T (2014) Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med 138(6):794\u2013802. https:\/\/doi.org\/10.5858\/arpa.2012-0762-OA","journal-title":"Arch Pathol Lab Med"},{"key":"4345_CR27","first-page":"77","volume":"147","author":"Y Su","year":"2017","unstructured":"Su Y, Goncalves T, Dias-Santagata D, Hoang MP (2017) Immunohistochemical detection of ROS1 fusion. Am J Clin Pathol 147:77\u201382","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"4345_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.32074\/1591-951X-756","volume":"114","author":"P Bironzo","year":"2022","unstructured":"Bironzo P, Melocchi L, Monica V, Trebeschi D, Barbieri F, Maiello E, Migliorino MR, Lombardi A, Tiseo M, Righi L, Graziano P, Rossi G, Novello S (2022) Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. Pathologica 114(4):278\u2013287. https:\/\/doi.org\/10.32074\/1591-951X-756","journal-title":"Pathologica"},{"key":"4345_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12308-023-00531-0","volume":"16","author":"S Fernandez-Pol","year":"2023","unstructured":"Fernandez-Pol S, Ferreira CR, Manohar V et al (2023) Comparison of two immunohistochemical staining protocols for ALK demonstrates non-inferiority of a 5A4 clone-based protocol versus an ALK01 clone-based protocol for the diagnosis of ALK + anaplastic large cell lymphoma. J Hematop 16:1\u20135","journal-title":"J Hematop"},{"key":"4345_CR30","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1002\/cncr.32422","volume":"125","author":"PO Fiset","year":"2019","unstructured":"Fiset PO, Labb\u00e9 C, Young K et al (2019) Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center\u2019s results in population-based reflex testing. Cancer 125:4043\u20134051","journal-title":"Cancer"},{"key":"4345_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jtho.2017.01.020","volume":"12","author":"T Thorne-Nuzzo","year":"2017","unstructured":"Thorne-Nuzzo T, Williams C, Catallini A et al (2017) A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with crizotinib. J Thorac Oncol 12:804\u2013813","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4345_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1586\/14737159.2016.1172963","volume":"16","author":"E Conde","year":"2016","unstructured":"Conde E, Hernandez S, Prieto M, Martinez R, Lopez-Rios F (2016) Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn 16(6):707\u2013713. https:\/\/doi.org\/10.1586\/14737159.2016.1172963","journal-title":"Expert Rev Mol Diagn"},{"key":"4345_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/PAI.0000000000000451","volume":"25","author":"CC Cheung","year":"2017","unstructured":"Cheung CC, D\u2019arrigo C, Dietel M et al (2017) Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine: Part 1: fit-for-purpose approach to classification of clinical immunohistochemistry biomarkers. Appl Immunohistochem Mol Morphol 25:4\u201311","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4345_CR34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/PAI.0000000000000267","volume":"23","author":"CC Cheung","year":"2015","unstructured":"Cheung CC, Garratt J, Won J et al (2015) Developing ALK immunohistochemistry and in situ hybridization proficiency testing for non-small cell lung cancer in Canada: Canadian immunohistochemistry quality control challenges and successes. Appl Immunohistochem Mol Morphol 23:677\u2013681","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04345-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04345-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04345-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:10:36Z","timestamp":1772694636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04345-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4345"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04345-6","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"M.R. Van Bockstal previously received institutional research and\/or travel support from Roche and Sysmex, as well as institutional consulting fees for being a member of advisory boards of AstraZeneca and Sakura, all unrelated to the present work. The other authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}